Onconic Therapeutics Inc. (KOSDAQ:476060)

South Korea flag South Korea · Delayed Price · Currency is KRW
16,560
-480 (-2.82%)
At close: Feb 6, 2026
362.25%
Market Cap743.34B +277.2%
Revenue (ttm)46.65B +529.9%
Net Income16.75B
EPS1,513.84
Shares Out44.89M
PE Ratio10.94
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume530,819
Average Volume959,500
Open16,400
Previous Close17,040
Day's Range15,920 - 16,790
52-Week Range3,138 - 26,600
Betan/a
RSI36.26
Earnings DateMar 13, 2026

About Onconic Therapeutics

Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer. The company was founded in 2020 and is based in Seoul, South Kor... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 476060
Full Company Profile

Financial Performance

Financial Statements